Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

On Friday 23 October, patients, carers, researchers and healthcare professionals gathered together at the Oxford Spires Four Pillars Hotel for the first ever UK day dedicated to primary lateral sclerosis.

What is PLS?

Primary lateral sclerosis (PLS) is a very rare form of motor neurone disease (MND) that progresses slowly. Typically, it affects people over 50, but it can affect younger people too. PLS affects the nerve cells (upper motor neurons) that send messages from the brain down to the spinal cord to control other cells (lower motor neurons) that are directly responsible for making muscles work. The consequence of this damage is that muscles develop stiffness and loss of function. Although the limbs are affected in almost all cases, symptoms in the muscles used for speech and swallowing are also common.

It is not known what causes PLS, and research is ongoing. Researchers believe that a combination of environmental and genetic factors play a part, although it is not thought to be an inherited condition.

The day's programme

About 100 people attended the event, which was organised by the Oxford MND Centre and supported by the MND Association. It included expert talks from researchers at the University of Oxford and the University of Sheffield, as well as two question and answer sessions. For many people, one of the main benefits of the day was to meet others who had been diagnosed with the same condition. In particular, there is a Facebook group for PLS patients and their carers, and many of them were meeting in person for the first time.

Martin Turner and Kevin Talbot from the Nuffield Department of Clinical Neurosciences (NDCN) at the University of Oxford talked about the history of the condition and its clinical features, discussing its relationship to more common types of motor neuron disease. Olaf Ansorge, also based in NDCN, gave an overview of the histopathology of PLS, and Christopher McDermott from Sheffield explained what other diseases can teach us about the condition.

Ricarda Menke (NDCN & Oxford Centre for Functional Magnetic Resonance of the Brain) and Malcom Proudfoot (NDCN & Oxford Centre for Human Brain Activity) presented two key techniques for furthering research into PLS: magnetic resonance imaging and magnetoencephalography. A key feature of all these presentations was the honesty with which the researchers presented their limited understanding of this rare disease, along with their determination and optimism regarding future discoveries.

Dr Mary-Kay Floeter from the National Institutes of Health in Washington, USA, gave a much-anticipated talk in the afternoon on her unique work to understand the natural history of the condition. This was followed by a presentation from Oxford MND Centre staff Kevin Talbot and Rachel Marsden on symptom management. The day concluded with a session where patients’ questions on how to manage symptoms were addressed by the panel.

Find out more

Similar stories

New study shows clinical symptoms for Alzheimer’s can be predicted in preclinical models

Establishing preclinical models of Alzheimer’s that reflect in-life clinical symptoms of each individual is a critically important goal, yet so far it has not been fully realised. A new collaborative study from the University of Oxford has demonstrated that clinical vulnerability to an abnormally abundant protein in Alzheimer’s brain is in fact reflected in individual patient induced pluripotent stem cell-derived cortical neurons.

New insights gained into how the brain encodes information about the world

Scientists have developed a new way to test the theory that active neurons can change what they signal in the world, rather than keeping a stable correspondence to things (such as a features of an object, or ideas).

Oxford and Quinnipiac researchers discuss integrated clinical care, education, and research in multiple sclerosis

Mount Sinai Rehabilitation Hospital's Mandell Center for Multiple Sclerosis Care and Neuroscience Research welcomed University of Oxford partners in September. Stakeholders from University of Oxford and Quinnipiac University met to discuss ongoing research and future opportunities to develop a Mandell MS Center concept of care in the UK.

Royal Academy of Engineering Research Fellowship

Dr Rezvan Farahibozorg has received one of 17 Royal Academy of Engineering Research Fellowships for 2022.

Repurposed drug could help patients with motor neuron disease

A drug typically used to treat enlarged prostates and high blood pressure has shown promise as a potential new therapy for motor neuron disease (MND), according to a new study.